search
Back to results

A Study on the Endoscopic Treatments of Hemorrhoids

Primary Purpose

Hemorrhoids

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
performing endoscopy
Sponsored by
Fangyu Wang
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemorrhoids

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Sign a written informed consent form.
  2. Age 18-80 years with clinical symptoms of hemorrhoids.
  3. Subjects able to follow the follow-up schedule, able to describe symptoms objectively and able to cooperate in completing the scale.
  4. non-breastfeeding pregnant women and those with no pregnancy planned during the trial
  5. not participating in various clinical trials in the 3 months prior to and during the trial
  6. Not taking long-term anticoagulant drugs (e.g., clopidogrel, aspirin, triptans, etc.) or have stopped taking them for 5-7 days.

Exclusion Criteria:

  1. those with severe organ insufficiency of the heart, brain, lungs and kidneys
  2. those who cannot tolerate endoscopic treatment
  3. those with severe coagulation disorders
  4. men with a history of severe prostate enlargement
  5. with severe intestinal diseases: colon malignancy, ulcerative colitis, Crohn's disease, anal fistula, anal fissure, acute thrombosed internal hemorrhoids
  6. those who are allergic to sclerosing agents
  7. Those who, in the opinion of the investigator, cannot be enrolled for any reason.

Sites / Locations

  • Jinling hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

endoscopic sclerotherapy

endoscopic rubber band ligation

endoscopic sclerotherapy combined with rubber band ligation

Arm Description

Patients with hemorrhoids will be treated with endoscopic sclerotherapy. Injection site is submucosa of hemorrhoid nucleus. Sclerosing agent makes the submucosal tissue fibrotic, and then fixes the hemorrhoidal tissue.

Patients with hemorrhoids will be treated with endoscopic rubber band ligation. The ligature position is above the mucosa of the hemorrhoid nucleus. Ligation of hemorrhoidal tissue can lead to ischemic necrosis of the prolapsed mucosa, which in turn leads to scar fixation. At the same time, the ligature also has the effect of lifting the tissue upward.

Patients with hemorrhoids will be treated with endoscopic sclerotherapy combined with rubber band ligation. Sclerotherapy first, followed by rubber band ligation. Sclerotherapy injection reduces the likelihood of ligature dislodgement.

Outcomes

Primary Outcome Measures

Total effective rate
Total effective rate includes effective rate and cure rate. Effective rate means that symptoms are better than before treatment;Cure rate refers to the percentage of symptoms that completely disappear.

Secondary Outcome Measures

Incidence of complications
Incidence of complications such as urinary retention, anal stricture, etc. within 1 year
Incidence of new symptoms
Incidence of new symptoms such as bleeding, pain, etc. within 1 year
Recurrence rate after treatment
Recurrence rate after 1 year of treatment
Patient satisfaction
A questionnaire was used to obtain patients' responses regarding their satisfaction with the treatment, with the following three options: satisfied, indifferent, and dissatisfied.
Endoscopic presentation of hemorrhoids
Circumferential distribution of hemorrhoids, the diameter of the largest hemorrhoids, presence of red color signs (change in the color of the surface of the rectal column in accordance with the general rules for endoscopic findings of esophagogastric varices)
Intraoperative situation
The amount of intraoperative bleeding and whether the patient had discomfort during the operation.
Number of days in hospital
Number of days in hospital
Hospitalization Costs
Hospitalization Costs
Incidence of needing re-treatment
Need for retreatment due to recurrence or worsening of symptoms

Full Information

First Posted
February 10, 2022
Last Updated
April 16, 2022
Sponsor
Fangyu Wang
Collaborators
The Second Affiliated Hospital of Nanjing University of Chinese Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT05268575
Brief Title
A Study on the Endoscopic Treatments of Hemorrhoids
Official Title
Comparative Study on Endoscopic Treatments for Hemorrhoids (METHOD): a Multicenter, Randomized Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
May 30, 2022 (Anticipated)
Primary Completion Date
September 1, 2024 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Fangyu Wang
Collaborators
The Second Affiliated Hospital of Nanjing University of Chinese Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Hemorrhoids is one of the most common anorectal diseases, can occur at any age and gender. Hemorrhoids generally do not have very serious clinical manifestations, but often bring huge life pressure and psychological burden to patients, so effective treatment is necessary. Traditional surgical treatment techniques, such as hemorrhoidectomy, may have defects such as anal pain and long recovery time. Recently, endoscopic hemorrhoid treatment has become a safe, effective and rapid rehabilitation treatment. Treatment of hemorrhoids treatment including endoscopic sclerotherapy, endoscopic rubber band ligation, endoscopic sclerotherapy combined with rubber band ligation, the three kinds of treatment methods have their own advantages, but existing research at home and abroad is still less and the comparison of various treatment methods lack of consensus. Our study is to compare the three kinds of treatment methods.
Detailed Description
In this trial, investigators plan to conduct a multicenter, randomized controlled clinical trial. The leader of the sponsoring organization strictly implements oversight of the protocol. Investigators intend to compare the total efficiency of the endoscopic sclerotherapy group, the endoscopic rubber band ligation group, and the endoscopic sclerotherapy combined with rubber band ligation group for the treatment of hemorrhoids. The Department of Gastroenterology at Jinling Hospital will take full charge of this trial, including recruitment of patients, endoscopic treatment, in-hospital nursing, follow-up work, etc. Informed consent forms from every patient will be signed before enrollment, and approval from the Ethical Committees of Jinling Hospital has been obtained. After patients will be admitted to the hospital and sign informed consent, they will be randomly assigned to the endoscopic sclerotherapy group, the endoscopic rubber band ligation group, and the endoscopic sclerotherapy combined with rubber band ligation group in a 1:1:1 ratio of 130 patients in each group, and the assignment will be done by a mobile client randomization tool. Patients in each group completed bowel preparation according to the same requirements and performed the appropriate endoscopic treatment. The sclerosing agent is polydocanol and the ligature model is MBL-6-F. Our main observation is the overall effectiveness rate (the ratio of the number of people whose symptoms improved and the number of people whose symptoms completely disappeared to the total number of people). Our secondary observation indicators are the incidence of complications (such as urinary retention, prostatic abscess, fecal incontinence, rectal stricture, infection, bacteraemia, etc.) within 1 year after hemorrhoid treatment, the presence of new symptoms within 1 year after treatment, the recurrence rate after treatment, patient satisfaction, endoscopic performance of hemorrhoids, intraoperative conditions, hospital days, hospital costs, the need for retreatment due to recurrence or worsening of symptoms, blood routine, urine routine, fecal routine, coagulation function, blood biochemistry, etc. Investigators will observe the status of patients 48 hours after treatment, 3 month after treatment, 6 months after treatment, 9 months after treatment, and 1 year after treatment. Follow-up will be conducted through online questionnaires or telephone callbacks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhoids

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
285 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
endoscopic sclerotherapy
Arm Type
Experimental
Arm Description
Patients with hemorrhoids will be treated with endoscopic sclerotherapy. Injection site is submucosa of hemorrhoid nucleus. Sclerosing agent makes the submucosal tissue fibrotic, and then fixes the hemorrhoidal tissue.
Arm Title
endoscopic rubber band ligation
Arm Type
Experimental
Arm Description
Patients with hemorrhoids will be treated with endoscopic rubber band ligation. The ligature position is above the mucosa of the hemorrhoid nucleus. Ligation of hemorrhoidal tissue can lead to ischemic necrosis of the prolapsed mucosa, which in turn leads to scar fixation. At the same time, the ligature also has the effect of lifting the tissue upward.
Arm Title
endoscopic sclerotherapy combined with rubber band ligation
Arm Type
Experimental
Arm Description
Patients with hemorrhoids will be treated with endoscopic sclerotherapy combined with rubber band ligation. Sclerotherapy first, followed by rubber band ligation. Sclerotherapy injection reduces the likelihood of ligature dislodgement.
Intervention Type
Other
Intervention Name(s)
performing endoscopy
Other Intervention Name(s)
drugs, device
Intervention Description
Hemorrhoids will be treated by endoscopic sclerotherapy or endoscopic rubber band ligation or endoscopic sclerotherapy combined with rubber band ligation
Primary Outcome Measure Information:
Title
Total effective rate
Description
Total effective rate includes effective rate and cure rate. Effective rate means that symptoms are better than before treatment;Cure rate refers to the percentage of symptoms that completely disappear.
Time Frame
one year
Secondary Outcome Measure Information:
Title
Incidence of complications
Description
Incidence of complications such as urinary retention, anal stricture, etc. within 1 year
Time Frame
1 year
Title
Incidence of new symptoms
Description
Incidence of new symptoms such as bleeding, pain, etc. within 1 year
Time Frame
1 year
Title
Recurrence rate after treatment
Description
Recurrence rate after 1 year of treatment
Time Frame
1 year
Title
Patient satisfaction
Description
A questionnaire was used to obtain patients' responses regarding their satisfaction with the treatment, with the following three options: satisfied, indifferent, and dissatisfied.
Time Frame
1 year
Title
Endoscopic presentation of hemorrhoids
Description
Circumferential distribution of hemorrhoids, the diameter of the largest hemorrhoids, presence of red color signs (change in the color of the surface of the rectal column in accordance with the general rules for endoscopic findings of esophagogastric varices)
Time Frame
1 year
Title
Intraoperative situation
Description
The amount of intraoperative bleeding and whether the patient had discomfort during the operation.
Time Frame
1 year
Title
Number of days in hospital
Description
Number of days in hospital
Time Frame
1 year
Title
Hospitalization Costs
Description
Hospitalization Costs
Time Frame
1 year
Title
Incidence of needing re-treatment
Description
Need for retreatment due to recurrence or worsening of symptoms
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Sign a written informed consent form. Age 18-80 years with clinical symptoms of hemorrhoids. Subjects able to follow the follow-up schedule, able to describe symptoms objectively and able to cooperate in completing the scale. non-breastfeeding pregnant women and those with no pregnancy planned during the trial not participating in various clinical trials in the 3 months prior to and during the trial Not taking long-term anticoagulant drugs (e.g., clopidogrel, aspirin, triptans, etc.) or have stopped taking them for 5-7 days. Exclusion Criteria: those with severe organ insufficiency of the heart, brain, lungs and kidneys those who cannot tolerate endoscopic treatment those with severe coagulation disorders men with a history of severe prostate enlargement with severe intestinal diseases: colon malignancy, ulcerative colitis, Crohn's disease, anal fistula, anal fissure, acute thrombosed internal hemorrhoids those who are allergic to sclerosing agents Those who, in the opinion of the investigator, cannot be enrolled for any reason.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fangyu Wang
Phone
+8613515100636
Email
wangfy65@nju.edu.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Zhihao Ding
Phone
+8615061586037
Email
d382428060@163.com
Facility Information:
Facility Name
Jinling hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210002
Country
China

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31583307
Citation
Yamana T. Japanese Practice Guidelines for Anal Disorders I. Hemorrhoids. J Anus Rectum Colon. 2018 May 25;1(3):89-99. doi: 10.23922/jarc.2017-018. eCollection 2017.
Results Reference
background
PubMed Identifier
15131807
Citation
Madoff RD, Fleshman JW; Clinical Practice Committee, American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of hemorrhoids. Gastroenterology. 2004 May;126(5):1463-73. doi: 10.1053/j.gastro.2004.03.008. No abstract available.
Results Reference
background
PubMed Identifier
33511050
Citation
Ma W, Guo J, Yang F, Dietrich CF, Sun S. Progress in Endoscopic Treatment of Hemorrhoids. J Transl Int Med. 2020 Dec 31;8(4):237-244. doi: 10.2478/jtim-2020-0036. eCollection 2020 Dec.
Results Reference
background
PubMed Identifier
29420423
Citation
Davis BR, Lee-Kong SA, Migaly J, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Hemorrhoids. Dis Colon Rectum. 2018 Mar;61(3):284-292. doi: 10.1097/DCR.0000000000001030. No abstract available.
Results Reference
background
PubMed Identifier
22980596
Citation
Awad AE, Soliman HH, Saif SA, Darwish AM, Mosaad S, Elfert AA. A prospective randomised comparative study of endoscopic band ligation versus injection sclerotherapy of bleeding internal haemorrhoids in patients with liver cirrhosis. Arab J Gastroenterol. 2012 Jun;13(2):77-81. doi: 10.1016/j.ajg.2012.03.008. Epub 2012 Apr 24.
Results Reference
background
PubMed Identifier
12780901
Citation
Kanellos I, Goulimaris I, Christoforidis E, Kelpis T, Betsis D. A comparison of the simultaneous application of sclerotherapy and rubber band ligation, with sclerotherapy and rubber band ligation applied separately, for the treatment of haemorrhoids: a prospective randomized trial. Colorectal Dis. 2003 Mar;5(2):133-8. doi: 10.1046/j.1463-1318.2003.00395.x.
Results Reference
background
PubMed Identifier
32003357
Citation
Abiodun AA, Alatise OI, Okereke CE, Adesunkanmi AK, Eletta EA, Gomna A. Comparative study of endoscopic band ligation versus injection sclerotherapy with 50% dextrose in water, in symptomatic internal haemorrhoids. Niger Postgrad Med J. 2020 Jan-Mar;27(1):13-20. doi: 10.4103/npmj.npmj_128_19.
Results Reference
background

Learn more about this trial

A Study on the Endoscopic Treatments of Hemorrhoids

We'll reach out to this number within 24 hrs